Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year. The top 10 deals [...]
The biotech index is more than a triple bagger ramp since 2010. Know that as long as the biopharm has equity (capital), research will continue with reckless abandon. Hopefully, with this ramp, the old guard will implement technology to bring more accurate outcomes. szimm
The biotech index is more than a triple bagger ramp since 2010. As a student of the market for over 20 years, with clinical research funding dropping, is there a top anywhere in sight? SZIMM Exclusive Interview with David Nierengarten, Ph.D., an Analyst at Wedbush Securities Covering the Biotechnology and Biopharmaceuticals Sector TWST: What's the FDA [...]
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. [...]
Puma Biotechnology Inc. (PBYI) said it will delay filing for U.S. regulatory approval of its experimental breast cancer treatment by as much as a year. The company’s shares fell 15 percent to $192.36 at 9:36 a.m. in New York, the most since June. The drugmaker announced yesterday that it would apply for Food and Drug [...]
http://www.forbes.com/sites/johnlamattina/2014/12/02/the-debate-over-the-cost-to-develop-a-new-drug/?partner=yahootix
Studyops, San Francisco California, is aggressively seeking a Rheumatologist to become the lead investigator on Clinical Trials. There are currently 1800 studies for RA listed on clinicaltrials.gov and 500 for Lupis. This is a huge area of development in the R&D space and an excellent opportunity for a Rheumatologist to participate in the advancement of [...]
Ref: PR Newswire, Financial Times, Bloomberg, Yahoo!Finance, The Wall Street Journal, The New York Times, ABC News, Otsuka) December 2nd, 2014 By: Matthew Dennis Otsuka announced Tuesday a definitive agreement to acquire Avanir Pharmaceuticals for $17.00 per share in cash, or approximately $3.5 billion, expanding its presence in neurologic diseases. The transaction, which has been [...]
http://timesofindia.indiatimes.com/home/science/HIV-losing-its-edge-evolving-into-milder-form-study-finds/articleshow/45349074.cms
The Biggest HIV/AIDS Research Breakthroughs Of 2014 http://www.huffingtonpost.com/2014/12/01/2014-hiv-aids-research_n_6251388.html
